Nothing Special   »   [go: up one dir, main page]

BR112015018491A2 - triterpenoides c-19-modificados com atividade inibidora de maturação de hiv - Google Patents

triterpenoides c-19-modificados com atividade inibidora de maturação de hiv

Info

Publication number
BR112015018491A2
BR112015018491A2 BR112015018491A BR112015018491A BR112015018491A2 BR 112015018491 A2 BR112015018491 A2 BR 112015018491A2 BR 112015018491 A BR112015018491 A BR 112015018491A BR 112015018491 A BR112015018491 A BR 112015018491A BR 112015018491 A2 BR112015018491 A2 BR 112015018491A2
Authority
BR
Brazil
Prior art keywords
inhibitory activity
hiv maturation
compounds
modified triterpenoids
hiv
Prior art date
Application number
BR112015018491A
Other languages
English (en)
Inventor
Regueiro-Ren Alicia
Lee Venables Brian
Swidorski Jacob
A Meanwell Nicholas
Sin Ny
Liu Zheng
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112015018491A2 publication Critical patent/BR112015018491A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

resumo patente de invenção: "triterpenoides c-19-modificados com atividade inibidora de maturação de hiv". a presente invenção refere-se a compostos tendo propriedades que afetam fármaco e biológicas, suas composições farmacêuticas e métodos de utilização. em particular, triterpenóides modificados por c-19 que possuem uma atividade antiviral única são proporcionados como inibidores de maturação de hiv, como representado por compostos de fórmulas (i) e (ii), em que r1 é como aqui definido e não representa um grupo isopropila ou isopropenila: (fórmula (i)) e (fórmula (ii)). estes compostos são úteis para o tratamento do hivhiv e aids.
BR112015018491A 2013-02-06 2014-02-04 triterpenoides c-19-modificados com atividade inibidora de maturação de hiv BR112015018491A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361761403P 2013-02-06 2013-02-06
PCT/US2014/014647 WO2014123889A1 (en) 2013-02-06 2014-02-04 C-19 modified triterpenoids with hiv maturation inhibitory activity

Publications (1)

Publication Number Publication Date
BR112015018491A2 true BR112015018491A2 (pt) 2017-07-18

Family

ID=50150818

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015018491A BR112015018491A2 (pt) 2013-02-06 2014-02-04 triterpenoides c-19-modificados com atividade inibidora de maturação de hiv

Country Status (15)

Country Link
US (1) US20140221361A1 (pt)
EP (1) EP2953960A1 (pt)
JP (1) JP6186010B2 (pt)
KR (1) KR20150115881A (pt)
CN (1) CN105121454A (pt)
AR (1) AR094684A1 (pt)
AU (1) AU2014215468B2 (pt)
BR (1) BR112015018491A2 (pt)
CA (1) CA2900124A1 (pt)
EA (1) EA027371B1 (pt)
IL (1) IL240289A0 (pt)
MX (1) MX2015010003A (pt)
SG (1) SG11201505639SA (pt)
TW (1) TW201443073A (pt)
WO (1) WO2014123889A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906889B2 (en) * 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
CA2993758A1 (en) 2015-07-28 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
CA2993753A1 (en) 2015-07-28 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
WO2017025901A1 (en) * 2015-08-11 2017-02-16 Hetero Research Foundation Novel c28-analogues with c3-modifications of triterpene derivatives as hiv inhibitors
US20180273579A1 (en) 2015-09-24 2018-09-27 Glaxosmithkline Intellectual Property (No.2) Limited Compounds with hiv maturation inhibitory activity
WO2017125870A1 (en) 2016-01-20 2017-07-27 Glaxosmithkline Intellectual Property (No.2) Limited Amine derivatives of lupanes with hiv maturation inhibitory activity
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
WO2017149518A1 (en) * 2016-03-04 2017-09-08 Hetero Labs Limited C-3 novel triterpene with c-17 amine derivatives as hiv inhibitors
US10493070B2 (en) 2016-06-30 2019-12-03 Viiv Healthcare Uk (No. 5) Limited Azadecalin derivatives as inhibitors of human immunodeficiency virus replication
JP2019528304A (ja) * 2016-08-31 2019-10-10 ヴィーブ ヘルスケア カンパニー 組み合わせ並びにその使用及び治療
WO2018044853A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Conpany Combinations and uses and treatments thereof
EP3784349B1 (en) 2018-04-24 2023-12-27 VIIV Healthcare UK (No.5) Limited Compounds with hiv maturation inhibitory activity
US11236122B2 (en) 2018-06-29 2022-02-01 Dfh Therapeutics Triterpene amine derivatives
RS64915B1 (sr) 2019-02-11 2023-12-29 Hetero Labs Ltd Novi derivati triterpena kao inhibitori hiv-a

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2694048B2 (ja) * 1991-05-09 1997-12-24 日立建機株式会社 建設機械の油圧駆動装置
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
FR2683531B1 (fr) * 1991-11-13 1993-12-31 Rhone Poulenc Rorer Sa Nouveaux derives du lupane, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
EP1730163A4 (en) 2004-03-17 2009-12-30 Panacos Pharmaceuticals Inc Pharmaceutical salts of 3-O- (3,3-dimethylsuccinyl) betulinic acid
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
CA2714049A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17.beta. lupane derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
DK2576586T3 (en) 2010-06-04 2015-11-23 Bristol Myers Squibb Co C-28 AMINES OF MODIFIED C-3-BETULIN ACID DERIVATIVES AS ANTI-HUMIDITY INHIBITORS
CN103038245B (zh) * 2010-06-04 2015-03-25 百时美施贵宝公司 作为hiv成熟抑制剂的c-3经修饰的桦木酸衍生物
EP2589208A1 (en) 2010-06-29 2013-05-08 Huawei Technologies Co., Ltd. Delegate gateways and proxy for target hosts in large layer 2 and address resolution with duplicated internet protocol addresses
MY162186A (en) 2011-01-31 2017-05-31 Viiv Healthcare Uk (No 4) Ltd C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
EP2670764B1 (en) 2011-01-31 2015-09-02 Bristol-Myers Squibb Company C-28 amines of c-3 modified betulinic acid derivatives as hiv maturation inhibitors
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
WO2013160810A2 (en) * 2012-04-24 2013-10-31 Hetero Research Foundation Novel betulinic acid derivatives as hiv inhibitors
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity

Also Published As

Publication number Publication date
AU2014215468B2 (en) 2017-05-18
AR094684A1 (es) 2015-08-19
TW201443073A (zh) 2014-11-16
CN105121454A (zh) 2015-12-02
SG11201505639SA (en) 2015-08-28
IL240289A0 (en) 2015-09-24
WO2014123889A1 (en) 2014-08-14
JP2016507558A (ja) 2016-03-10
EA027371B1 (ru) 2017-07-31
AU2014215468A1 (en) 2015-09-24
US20140221361A1 (en) 2014-08-07
MX2015010003A (es) 2015-10-30
EP2953960A1 (en) 2015-12-16
KR20150115881A (ko) 2015-10-14
JP6186010B2 (ja) 2017-08-23
EA201591406A1 (ru) 2015-12-30
CA2900124A1 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
BR112015018491A2 (pt) triterpenoides c-19-modificados com atividade inibidora de maturação de hiv
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
EA201590450A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
MX355267B (es) Análogos de carba-nucleósido 2´-sustituidos para tratamiento antivírico.
BR112016005270A2 (pt) compostos de aza-piridona, composições farmacêuticas e seus usos
DOP2015000245A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos
BR112017023764A2 (pt) derivados de ciclohexano substituído por amido
EA201591586A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
BR112015016793A2 (pt) compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim
CO7240369A2 (es) Ácido 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
BR112012030810A2 (pt) "c-28 amidas de derivados de ácido c-3 betulínico modificados como inibidores de maturação de hiv"
BR112015016315A2 (pt) fluoro-[1,3]oxazinas como inibidores de bace1
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
UY33776A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
BR112014006559A2 (pt) derivados do ácido betulínico com atividade antiviral
BR112014023384A2 (pt) inibidores de bace de di-hidro-tiazina e di-hidro-oxazina espirocíclicos, e composições e usos dos mesmos
DOP2016000253A (es) Nuevos compuestos
BR112016024571A2 (pt) composto de 1,2,4-triazina dissubstituído
DOP2015000169A (es) Compuestos tetracíclicos sustituidos con heterociclo y usos de los mismos para el tratamiento de enfermedades víricas
DOP2014000059A (es) Derivados de estra–1,3,5(10),16–tetraen–3–carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
EA201500851A1 (ru) ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3)
DOP2017000244A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap)

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]